Octagon Capital Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Octagon Capital Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$180M	Sell	1,841,667 -105,000	-5%	-$9.17M	16.14%	1
2026 Q1	$163M	Sell	1,946,667 -470,000	-19%	-$27.2M	18.08%	1
2025 Q4	$99.6M	Hold	2,416,667	–	–	12.09%	2
2025 Q3	$95.1M	Buy	2,416,667 +75,000	+3%	+$1.92M	14.41%	2
2025 Q2	$43.6M	Hold	2,341,667	–	–	9.57%	1
2025 Q1	$42.5M	Buy	2,341,667 +231,500	+11%	+$5.1M	8.22%	3
2024 Q4	$46M	Buy	2,110,167 +363,500	+21%	+$9.35M	7.57%	3
2024 Q3	$47.8M	Hold	1,746,667	–	–	7.44%	4
2024 Q2	$45.2M	Buy	1,746,667 +366,000	+27%	+$8.8M	7.1%	2
2024 Q1	$41.4M	Buy	1,380,667 +826,667	+149%	+$18M	4.96%	3
2023 Q4	$5.76M	Buy	554,000 +74,000	+15%	+$817K	0.92%	23
2023 Q3	$6.56M	Buy	480,000 +445,625	+1,296%	+$5.61M	1.01%	22
2023 Q2	$417K	Buy	+34,375	New	+$391K	0.06%	39

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Octagon Capital Advisors's DNTH Position: Q2 2026 in Review

Octagon Capital Advisors reduced its Dianthus Therapeutics (DNTH) stake by 5.4% in Q2 2026, selling an estimated $9.17M and leaving 1,841,667 shares worth $180M. The position accounts for 16.14% of the portfolio, ranked #1.

Octagon Capital Advisors first reported a position in DNTH in Q2 2023 and has held it in 13 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Octagon Capital Advisors held 1,841,667 shares of Dianthus Therapeutics worth $180M as of Q2 2026.
Octagon Capital Advisors sold 105,000 Dianthus Therapeutics shares in Q2 2026, an estimated $9.17M.
Dianthus Therapeutics made up 16.14% of Octagon Capital Advisors's portfolio in Q2 2026, its #1 holding.
Octagon Capital Advisors first reported a position in Dianthus Therapeutics in Q2 2023 and has held it in 13 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.